Daily Alpha · Reddit
· Post-Market Alpha · by Buzzberg Research
Reddit is split between AI-infrastructure conviction and valuation caution, with GME warrant mechanics, memory pricing, and a broad set of single-name value and biotech theses.
Themes on this desk
GameStop warrants
Warrants expire October 30 at a $32 strike versus a ~$25 share price, with debate over whether insider buying is aimed at forcing them into the money and whether exercise is value-destructive.
Memory pricing
Samsung plans to triple HBM prices next year, and a Micron analysis argues Q4 growth was almost entirely price with only about 26% of revenue genuinely price-protected.
AI capex and power
ERCOT's 467 GW interconnection queue dwarfs the ~9 GW approved to energize, and AI infrastructure spend is projected to average 3.6% of US GDP.
Highest engagement
by score · day changeFlutter long thesis: Brazil ban and index forced selling create a ~$120 probability-weighted target
Post argues Flutter Entertainment (FLUT) fell roughly 67% on MSCI EAFE index deletion forced selling plus prediction-market fears, then another ~25% from $100 to $75 on Brazil's betting ban, which the author models as only about a $5 DCF haircut even pessimistically. With sell-side largely maintaining estimates, the author sets a probability-weighted price target of about $120 and argues the market is pricing roughly a 30% bankruptcy probability, with low active ownership and profitable shorts setting up a rebound.
My probability weighted (with a pessimistic skew and conservative assumptions) PT is about $120.
A large-cap gaming operator trading as if near-distress on a regulatory headline that the author models as immaterial would be a significant mispricing if the DCF work holds, with forced index selling creating a technical rather than fundamental drawdown.
Watch Brazilian regulatory developments on the betting ban, FLUT price action toward $120, and whether sell-side estimates remain unchanged.
Source →Adobe Q3 2026: organic ARR growth 9.3% and first single-digit RPO print since early FY2023
Poster strips out Semrush and finds Adobe's organic ARR growth was just 9.3%, with RPO up only 8% YoY — the first single-digit RPO print since early fiscal 2023. Management calls it a timing effect (RPO always jumps in Q4), but the poster warns that if Q4 doesn't catch up, the AI disruption thesis becomes fact rather than theory.
RPO grew only 8% YoY — the first single-digit RPO print since early fiscal 2023.
RPO is the forward-looking contract metric for Adobe; a second consecutive weak print would validate the AI-disruption bear case and undermine the cheap-valuation bull argument.
Watch Adobe's Q4 FY2026 RPO growth — a reacceleration back to double digits confirms the timing explanation; another single-digit print confirms structural AI erosion.
Source →Tencent reverse-DCF implies sub-zero perpetual growth despite ~14% revenue growth and ~11% three-year CAGR
Poster screens HK/China value names and finds Tencent near the top: EBIT/TEV 98th percentile, FCF yield 88th percentile, ~15% average ROIC over four years, Piotroski 7/9, Altman Z 4.1, Beneish -2.65, trading around 421 HKD. A reverse-DCF off the current price implies perpetual growth under -1%, essentially flat, versus ~14% revenue growth last year and ~11% CAGR over three years — the opposite of the usual value trap. He flags two open modeling questions: whether to back out the large investment book (equity-method income running through the income statement) from enterprise value, and whether an ~8% CAPM discount rate off a 0.74 beta is too low for a Chinese platform with regulatory and export-control tail risk.
Reverse-DCF off the current price implies perpetual growth under -1%, basically flat.
If the reverse-DCF read is right, the market is pricing Tencent as a mature no-growth business while it still compounds double digits, meaning the discount is either a genuine regulatory/export-control risk premium or a mispricing — a large-cap, high-liquidity way to express a China platform re-rating view.
Watch Whether the implied growth gap closes via multiple expansion or via estimate cuts; specifically, any change in regulatory/export-control headlines and the next quarterly revenue growth print versus the ~11-14% trend would confirm or break the thesis.
Source →Brent short thesis: war-risk premium unwinding as Middle East exports recover
Author argues Brent near $100/bbl is more overvalued now than at the war's start because the catastrophic Hormuz-closure scenario has not materialized, both sides have incentives to keep some oil trade flowing, and terminal/pipeline disruptions are typically bypassed or repaired within days to weeks. Middle East crude exports are cited at ~16.3 million b/d versus 19.5 million b/d pre-war, with 1.5-1.8 million b/d of new non-OPEC+ supply from the US, Brazil, Guyana, Canada, and Argentina coming online.
within days to weeks. Middle East crude exports are currently around 16.3 million b/d compared to 19.5 million b/d before
If the war-risk premium is indeed unwinding while supply additions land, Brent could mean-revert lower even with geopolitical headlines ongoing, pressuring energy equities and inflation expectations.
Watch Track Middle East export volumes recovering toward 19.5 million b/d and confirmation of the 1.5-1.8 million b/d non-OPEC+ additions; a sustained Brent break below the pre-war range would validate, while renewed Hormuz disruption would invalidate.
Source →Q3 2026: S&P 500 up 2.25% while mid-caps and small-caps fell sharply
Author reports Q3 2026 price changes: S&P 500 +168.31 points (+2.25%), S&P MidCap 400 -223.59 (-5.85%), Russell 2000 -215.73 (-7.16%), framing this as a need for broadening out given sticky inflation, rising yields, and supply shock.
**-5.85%** **Russell 2000 Index** **-215.73** **-7.16%** Need broadening out for growth to be sustainable in midst of sticky inflation, rising
Extreme large-cap versus small/mid-cap divergence in a quarter with rising yields and inflation suggests narrow, fragile leadership; lack of broadening would make index-level growth unsustainable.
Watch Track whether Russell 2000 and MidCap 400 close the performance gap versus the S&P 500 in Q4; continued divergence would confirm the narrow-leadership concern.
Source →Most argued
by comments per upvoteSLS bear case: GPS peak sales model implies $4.36/share versus current price
Author models Sellas Life Sciences' GPS opportunity using AML incidence, 70% CR1, half relapse, 60% CR2, 45% non-transplantable, yielding ~4,400 patients/yr across US/EU/Japan; at 65% uptake and ~$240k per course (9.5 injections at $25k list, off Onureg AWP) with 80% PoS, peak sales are ~$362m, giving $4.36/share. Even with guaranteed approval and every eligible patient treated, the model yields $6.78.
We get peak sales \~$362m. I used 80% PoS.
If the patient-population math is even roughly right, SLS equity is pricing a far broader label than the data support, creating asymmetric downside if the market re-rates to the CR1-only opportunity.
Watch Watch for SLS guidance on label expansion, partnership announcements, or trial enrollment updates; any move toward a CR1-only label would validate the bear case, while a partner-funded Onureg-scale trial would challenge it.
Source →